SPL026 (DMT fumarate) is currently undergoing phase II clinical trials investigating its use along with supportive psychotherapy as a potential cure for key depressive dysfunction. New receptors for DMT have been discovered and a potential role for DMT as a neuroprotectant and/or neuroregenerative agent has been advised. Hallucinogens happen to https://jasperwzyyv.canariblogs.com/details-fiction-and-dmt-42601039